🇺🇸 FDA
Patent

US 8105598

Human monoclonal antibodies that specifically bind IGF-II

granted A61KA61K2039/505A61P

Quick answer

US patent 8105598 (Human monoclonal antibodies that specifically bind IGF-II) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K2039/505, A61P, A61P35/00, A61P35/04